A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of MS-553 in healthy volunteers. Endpoints are safety, tolerability, and pharmacokinetics. Subjects are dosed for 14 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants

NCT03993704

Healthy

COMPLETED PHASE1

A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers

NCT05366634

Healthy Volunteers

COMPLETED PHASE1

Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants

NCT07281703

Healthy

NOT_YET_RECRUITING PHASE1

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

NCT05653037

Healthy Volunteers

ACTIVE_NOT_RECRUITING PHASE1

First-in-Human Trial of Oral AN2-502998

NCT07024589

Healthy Volunteers

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety and PK in Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MS-553

MS-553 oral tablet BID x 14 days

Group Type EXPERIMENTAL

MS-553

Intervention Type DRUG

Study Drug

Placebo

Placebo oral tablet BID x 14 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo to MS-553

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MS-553

Study Drug

Intervention Type DRUG

Placebo

Matching placebo to MS-553

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* In good general health with BMI 18 to 32 kg/m2. Females must be nonpregnant, nonlactating, postmenopausal at least 2 years or surgically sterilized at least 6 months prior